Categories: BioTechDevelopmentPlatform
The title of American academician team and the title of an expert of one-thousand people, specializing in oncolytic virus immunity and targeted gene therapy of solid tumors.
Investors 3
Mentions in press and media 5
| Date | Title | Description | Source |
| 08.08.2021 | ImmVira's MVR-C5252 Targeting Brain Tumor Obtained US FDA's ... |
SHENZHEN, China, Aug. 8, 2021 /PRNewswire/ -- ImmVira announces MVR-C5252 targeting Glioblastoma h... | prnewswire... |
| 18.07.2021 | ImmVira Launches Pilot-scale Production Line to Expedite the... |
SHENZHEN, China, July 18, 2021 /PRNewswire/ -- On July 18, 2021, ImmVira inaugurated a pilot-scale... | prnewswire... |
| 24.09.2020 | ImmVira Group Company Raises US$10M in Strategic Series B Pl... | ImmVira Group Company, a Chinese biotechnology company focused on the development of new generation ... | finsmes.co... |
| 15.06.2020 | ImmVira Raises $58M in Series B Financing | Immvira Group Company, a Shenzen, China-based biotechnology company focused on the development of ne... | finsmes.co... |
| - | Immvira | “Oncolytic Immunotherapy (Oncolytic Immunotherapy)” | fastfounde... |
Reviews 0
